Abstract：
Opicapone (OPC) is a third-generation peripheral catechol-O-methyl transferase inhibitor (COMT-i) approved as add-on therapy to levodopa/DOPA decarboxylase inhibitors (DDCI) combinations in Parkinson\'s disease (PD) patients with end-of-dose motor fluctuations. While the OPC effectiveness on motor symptoms is well known, there is still uncertainty about the timing of introduction, the management of levodopa dose, and the efficacy on non-motor symptoms (NMS).
A group of PD experts participated in a consensus activity composed of the Nominal Group Technique (NGT) and the Delphi method to better define the role of OPC. A list of statements was defined with the NGT and voted on through an online Delphi process by a panel of 85 Italian clinicians.
24 statements were selected for the Delphi voting. Most statements (n=15, 62%) reached a consensus. A wide agreement was reached about the efficacy of OPC in treating motor fluctuations, including early morning akinesia and nocturnal akinesia. The panel widely agreed about the effectiveness of OPC in early fluctuating patients. The long-lasting inhibitory effect of OPC was recognized as an advantage over other COMT-i, resulting in a single daily dose and greater ease of introduction into the levodopa therapeutic regimen.
The efficacy of OPC observed in the clinical trials for the management of PD patients with motor fluctuations is also experienced in clinical practice. The review of the current positioning of OPC from the late to early stages of the disease may represent an important step in the evolution of the PD therapeutic approach.
A group of PD experts participated in a consensus activity composed of the Nominal Group Technique (NGT) and the Delphi method to better define the role of OPC. A list of statements was defined with the NGT and voted on through an online Delphi process by a panel of 85 Italian clinicians.
24 statements were selected for the Delphi voting. Most statements (n=15, 62%) reached a consensus. A wide agreement was reached about the efficacy of OPC in treating motor fluctuations, including early morning akinesia and nocturnal akinesia. The panel widely agreed about the effectiveness of OPC in early fluctuating patients. The long-lasting inhibitory effect of OPC was recognized as an advantage over other COMT-i, resulting in a single daily dose and greater ease of introduction into the levodopa therapeutic regimen.
The efficacy of OPC observed in the clinical trials for the management of PD patients with motor fluctuations is also experienced in clinical practice. The review of the current positioning of OPC from the late to early stages of the disease may represent an important step in the evolution of the PD therapeutic approach.
摘要：
目的：Opicapone（OPC）是第三代外周儿茶酚-O-甲基转移酶抑制剂（COMT-i），已被批准为左旋多巴/多巴脱羧酶抑制剂（DDCI）组合的附加疗法。虽然OPC对运动症状的有效性是众所周知的，引入的时间仍然不确定，左旋多巴剂量的管理，以及对非运动症状（NMS）的疗效。
方法：一组PD专家参加了由标称组技术（NGT）和德尔菲法组成的共识活动，以更好地定义OPC的作用。NGT定义了声明列表，并由85名意大利临床医生组成的小组通过在线Delphi流程进行了投票。
结果：选择了24个陈述进行Delphi投票。大多数陈述（n=15，62％）达成了共识。关于OPC在治疗电机波动方面的功效达成了广泛共识，包括清晨运动不能和夜间运动不能。小组广泛同意OPC在早期波动患者中的有效性。OPC的持久抑制作用被认为是优于其他COMT-i的优势，导致单一的每日剂量和更容易引入左旋多巴治疗方案。
结论：在临床试验中观察到的OPC对患有运动波动的PD患者的疗效在临床实践中也有经验。从疾病的晚期到早期，对OPC当前定位的回顾可能代表了PD治疗方法发展的重要一步。
方法：一组PD专家参加了由标称组技术（NGT）和德尔菲法组成的共识活动，以更好地定义OPC的作用。NGT定义了声明列表，并由85名意大利临床医生组成的小组通过在线Delphi流程进行了投票。
结果：选择了24个陈述进行Delphi投票。大多数陈述（n=15，62％）达成了共识。关于OPC在治疗电机波动方面的功效达成了广泛共识，包括清晨运动不能和夜间运动不能。小组广泛同意OPC在早期波动患者中的有效性。OPC的持久抑制作用被认为是优于其他COMT-i的优势，导致单一的每日剂量和更容易引入左旋多巴治疗方案。
结论：在临床试验中观察到的OPC对患有运动波动的PD患者的疗效在临床实践中也有经验。从疾病的晚期到早期，对OPC当前定位的回顾可能代表了PD治疗方法发展的重要一步。
